Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1921-1940 of 3,900 trials

Sasanlimab for Muscle Invasive Bladder Cancer

We are studying whether sasanlimab can help patients with muscle invasive bladder cancer keep their bladder intact after initial treatment. The trial looks at survival rates and quality of life for participants.

Invasive Bladder Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Colchicine for Knee and Hip Osteoarthritis

We are studying whether colchicine can help reduce the need for knee or hip replacements in people with osteoarthritis. The trial also looks at its effects on pain, physical function, and overall quality of life.

Osteoarthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyRheumatology

Hidradenitis Suppurativa: Sonelokimab Treatment Study

We are testing a new injectable medication, sonelokimab, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it can improve symptoms compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyDermatology

Dental Implant Surgery: Antibiotics Study

We are investigating whether taking antibiotics helps patients recover better after dental implant surgery with bone regeneration and sinus elevation. This study compares the effects of antibiotics to a placebo on patient outcomes.

Implant Surgery with Guided Bone Regeneration6-12 monthsMonitoring phase (IV)6-10 visitsInvestigational MedicinesGynecology and ObstetricsInfectious DiseasesOrthopedics and TraumatologyOtolaryngology

Glycopyrronium for Asthma in Children

We are studying how well glycopyrronium works for children aged 6 to under 12 with asthma. The trial will also look at its safety and any side effects.

Asthma3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPediatricsPulmonology

Atopic Dermatitis: Methylprednisolone Aceponate Cream

We are comparing a new cream for atopic dermatitis with an existing treatment and a placebo. The goal is to see if it is more effective and safe for reducing symptoms.

Mild to Moderate Atopic DermatitisConfirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

NRAS Mutant Melanoma: Naporafenib + Trametinib Study

We are testing a new combination therapy for patients with previously treated NRAS mutant cutaneous melanoma. The goal is to see if it works better than standard treatment options in improving survival and managing the disease.

Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyOncology

Community-Acquired Pneumonia: Inhaled Levofloxacin Study

We are investigating whether inhaling levofloxacin helps improve health in patients with community-acquired pneumonia. This study includes individuals with and without pre-existing lung disease.

Community-acquired Pneumonia>2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesInfectious DiseasesPulmonology

Metastatic Breast Cancer: New HER2 Imaging Test

We are studying a new imaging method using 68Ga-ABS011 to see how well it detects HER2 status in metastatic breast cancer and other solid tumors. This may help improve diagnosis and treatment management.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineOncology

Prostate Cancer: CC 1 Antibody Study

We are evaluating a new antibody treatment for men whose prostate cancer has returned. The study aims to assess its safety and early signs of effectiveness.

Recurrent Prostate Cancer>2 yearsSafety phase (I)OncologyUrology

Advanced Liver Cancer: CT 01 and Everolimus Study

We are investigating whether CT 01 is safe to use alone or with Everolimus for patients with inoperable advanced liver cancer. This study aims to understand the safety of these treatment options.

Liver Cancer3-6 monthsSafety phase (I)HepatologyOncology

Hepatocellular Carcinoma: Triple Treatment Study

We are studying a combination of three medications for patients with non-resectable liver cancer. The goal is to see if this approach improves symptoms and quality of life compared to past treatments.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Rheumatoid Arthritis: Baricitinib and Anti-TNF Combination Study

We are investigating whether combining baricitinib with anti-TNF therapy helps patients with rheumatoid arthritis who haven't responded to other treatments. The study will also look at safety and how well patients can reduce their steroid use.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

Advanced Solid Tumors: KQB198 Treatment Study

We are investigating a new treatment called KQB198 for individuals with advanced solid tumors. The study aims to assess its safety and effectiveness, both alone and with other therapies.

Solid Tumour>2 yearsSafety phase (I)Oncology

Advanced Blood Cancers: KQB198 Treatment Study

We are investigating a new treatment called KQB198 for individuals with advanced hematologic malignancies. The study aims to assess its safety and effectiveness, both alone and with other therapies.

Advanced Blood Cancer>2 yearsSafety phase (I)HematologyOncology

Ulcerative Colitis: Filgotinib for Kids and Teens

We are studying the effects of filgotinib in children and teenagers with moderately to severely active ulcerative colitis. The trial aims to see if it helps achieve remission and improves quality of life.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

HYSTINDO Study: Indocyanine Green in Laparoscopic Hysterectomy

We are exploring how a special dye can help surgeons see blood flow in the vaginal area during laparoscopic hysterectomy. This study aims to improve surgical safety and outcomes for patients.

Total Hysterectomy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Fibrodysplasia Ossificans Progressiva: Fidrisertib Study

We are studying a new oral medication for people with fibrodysplasia ossificans progressiva to see if it can help prevent new bone growth and improve overall health. This trial includes both children and adults to evaluate its safety and effectiveness.

Fibrodysplasia Ossificans ProgressivaEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurology

Early Rheumatoid Arthritis: Biomarker Study for Abatacept

We are investigating if certain biomarkers can predict how well patients with early rheumatoid arthritis respond to abatacept treatment. This may help tailor therapies to individual needs.

Rheumatoid Arthritis3-6 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Crohn's Disease in Children: Mirikizumab Study

We are studying whether Mirikizumab can help children with moderately to severely active Crohn's Disease achieve better health compared to a placebo. This research aims to improve treatment options for young patients.

Crohn's Disease1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics